At 10,000L scale, producing 100 kg/year of A Mab cost:
No centrifugation used because A Mab’s small aggregates (5%) were shear-sensitive. A Mab A Case Study In Bioprocess Development
| Parameter | Lab (2 L) | Pilot (50 L) | Commercial (2,000 L) | |-----------|-----------|--------------|----------------------| | Temp (°C) | 37 → 33 (shift) | Same | Same | | pH | 7.0 → 6.9 (shift) | Same | Same | | DO (%) | 40 | 40 | 40 | | Agitation (tip speed) | 0.3 m/s | 0.35 m/s | 0.45 m/s | | Sparger type | Microsparger | Microsparger | Ring + micro | At 10,000L scale, producing 100 kg/year of A
This article presents . We will follow a hypothetical but representative IgG1 monoclonal antibody—let us call it "Mab-X"—through the four critical stages of bioprocess development: upstream processing (cell culture), downstream processing (purification), formulation, and scale-up. By examining the specific bottlenecks, optimization strategies, and analytical milestones of Mab-X, we will illustrate why bioprocess development is often the rate-limiting step in bringing lifesaving medicines to patients. The CHO cell line was transfected with a
The first step in the bioprocess development of A Mab was the creation of a stable and productive cell line. A Mab was produced in a Chinese Hamster Ovary (CHO) cell line, which is a commonly used host for the production of therapeutic proteins. The CHO cell line was transfected with a plasmid containing the gene encoding A Mab, and a clone with high productivity and stability was selected.